If you’ve noticed more conversations about GLP-1 medications and teenagers lately, you’re not imagining it. Prescriptions for adolescents have climbed sharply in the past few years, and a lot of parents are left with genuine questions and not a lot of clear, calm information to answer them. 

Maybe your child’s pediatrician brought it up as an option. Maybe you’ve seen headlines about rising use and wondered whether this is something worth discussing at your next appointment. 

Either way, this article isn’t here to tell you these medications are good or bad. It’s here to walk you through what the research actually shows, what the specific nutritional risks look like for a growing kid, and how to build the right support around your child if this is part of their care plan.

What the Current Research Says About GLP-1 Use in Adolescents

In 2023, the American Academy of Pediatrics released clinical practice guidelines recommending that doctors offer obesity medications, including GLP-1 medications, for kids aged 12 and older with obesity, as part of a broader treatment plan that also includes nutrition and lifestyle support.

This was a meaningful shift from the previous approach of watchful waiting, where families were often advised to focus solely on lifestyle changes and wait to see how a child’s weight trajectory developed over time. The new guidelines opened the door to a much more active treatment approach, and prescriptions followed quickly.

According to CDC data reported through the MMWR, the proportion of U.S. adolescents with obesity who were prescribed an obesity medication increased by approximately 300% in 2023 compared with 2020, the year after the FDA expanded approval of two obesity medications to include adolescents. Even so, only about 0.5% of adolescents with obesity received a prescription that year, with the large majority going to those with severe obesity. That’s a notable shift in a short period, and it reflects both growing physician comfort with prescribing these medications and rising parent interest in options beyond diet and exercise alone.

The clinical trial data on adolescent weight loss medication in this category is genuinely encouraging on the efficacy side. A structured review published in the journal Children found that liraglutide and semaglutide consistently produce clinically meaningful reductions in BMI, body weight, and waist circumference in adolescents, with modest improvements in blood pressure and minimal effects on cholesterol levels.

Currently, liraglutide and semaglutide are the two GLP-1 medications with FDA approval specifically for adolescents 12 and older with obesity, and a 2024 randomized trial (the SCALE Kids trial) published in the New England Journal of Medicine found that liraglutide also lowered BMI in children as young as 6, though no GLP-1 is yet approved for children under 12 outside of clinical trials.

Where the research is genuinely still catching up is long-term safety and development. The same review in Children noted that major gaps remain in the data, including a lack of long-term safety and growth information, limited pediatric-specific dosing research, and open questions about how these medications interact with puberty over time.

Researchers involved in this area of study have been clear that more longitudinal data is needed before some of these open questions can be fully answered. This isn’t a reason for alarm, but it is a reason for careful, ongoing monitoring rather than a set-it-and-forget-it approach once a prescription starts.

Nutritional Risks Specific to Growing Kids

This is the part of pediatric GLP-1 use that deserves the most attention from parents, because kids are not just small adults. They’re in the middle of active growth, and that changes the stakes around reduced appetite considerably.

A clinical review published in the journal Pediatrics by the American Academy of Pediatrics addressed this directly, stating that the risk of both micronutrient and macronutrient deficiency in children on GLP-1 medications needs to be better characterized, and that careful monitoring of nutritional intake is recommended for every child on these medications. 

This matters because a teenager’s body isn’t just maintaining itself. It’s actively building bone density, muscle mass, and supporting the hormonal changes of puberty, all of which require adequate fuel and specific nutrients to happen properly and on schedule.

Weight loss on these medications tends to include both fat and lean tissue, and the same AAP-published review noted that rapid weight loss can impair muscle strength or bone density in adolescents if resistance exercise and adequate protein intake aren’t specifically prioritized during treatment. This is a meaningfully different concern than in adults, since bone mass built during adolescence is a major predictor of skeletal health decades later. 

The teenage years are when the body lays down a significant portion of the bone density a person will carry for the rest of their life, which is exactly why researchers are paying close attention to this particular risk in younger patients.

There’s also a specific consideration for certain kids. The AAP review noted that populations with a higher baseline risk of restrictive eating patterns already face increased risk of micronutrient deficiency, and that this risk needs extra attention when combined with a medication that further reduces appetite. This is a good example of why nutrition for kids on GLP-1s cannot be a one-size-fits-all approach. 

Every child’s baseline eating patterns, growth trajectory, and specific health profile matter in shaping what kind of nutritional support they need. A child who was already a selective or inconsistent eater before starting treatment may need a different level of monitoring than a child who ate a wide variety of foods beforehand.

Researchers have also flagged ongoing questions about how reduced nutrient intake during adolescence might affect long-term bone development specifically, since bone accrual during the teenage years depends heavily on adequate calcium, vitamin D, and overall caloric sufficiency. 

None of this means GLP-1 medications are inappropriate for adolescents. It means that reduced appetite during a critical growth window requires more deliberate nutritional planning than it would for an adult who has already finished growing.

Building a Support Team Around Your Child

Given everything above, the most protective thing a parent can do if their child is on or considering a GLP-1 medication is to build a support team around the treatment, not just around the prescription itself.

A pediatric dietitian plays a genuinely central role here, and this isn’t a nice-to-have addition. Since the research points clearly to protein, micronutrient, and bone health risks that require deliberate management, having a professional who can assess your child’s specific intake and build a realistic eating plan around their reduced appetite is one of the most useful things you can put in place. 

A pediatric dietitian who understands both adolescent nutrition and GLP-1 medications specifically can help make sure your child’s growth, bone health, and muscle mass are being supported rather than compromised during treatment. This kind of specialized guidance tends to be far more useful than generic nutrition advice, since a growing adolescent on appetite-suppressing medication has genuinely different needs than an adult in the same situation.

Regular monitoring from your child’s prescribing physician matters just as much. This typically includes tracking growth curves, not just weight, along with periodic bloodwork to catch any emerging deficiencies early, and open conversations about appetite, energy levels, and mood as treatment continues. Growth curve tracking, in particular, is important because it gives a fuller picture than the number on a scale alone, showing whether a child’s height, weight, and overall development are progressing the way they should be for their age.

It’s also worth knowing what falls outside the nutritional picture entirely. Fatigue, difficulty concentrating, or mood changes can sometimes come up during any major change to a child’s eating patterns or medication regimen. But if a child was already showing signs of inattention, impulsivity, or difficulty with focus and organization before starting a GLP-1, and those patterns continue or seem unrelated to appetite or energy changes, that’s worth a separate conversation with their pediatrician about whether something like ADHD might be part of the picture. 

According to CHADD, ADHD is one of the most common neurodevelopmental conditions in children, and its symptoms are distinct from anything related to appetite or nutrition. If you’re noticing patterns that concern you, reviewing common ADHD symptoms can help you understand whether what you’re seeing warrants its own evaluation, entirely separate from anything related to a weight management medication. Keeping these two threads distinct matters, since conflating a medication side effect with an unrelated developmental condition can delay proper support for either issue.

Building this kind of team doesn’t need to happen all at once, and it doesn’t need to feel overwhelming. Starting with your child’s pediatrician and asking directly about nutritional monitoring and dietitian referrals is a reasonable first step, and the rest of the support system can build out from there as needed.

Conclusion

The research on GLP-1 medications for kids continues to develop, and the honest picture right now is one of real promise alongside real, well-documented gaps in long-term safety and growth data. What is clear is that reduced appetite during adolescence carries different stakes than it does in adulthood, simply because growing bodies have different, non-negotiable nutritional needs that don’t pause just because a medication is helping manage appetite.

If your child is on or considering one of these medications, the most useful thing you can do isn’t to worry more. It’s to make sure nutritional oversight is built into the plan from day one, not added later if something goes wrong. A pediatric dietitian, a physician tracking growth and bloodwork over time, and honest conversations about how your child is actually eating and feeling all matter here, and each piece supports the others.

Pediatric GLP-1 use isn’t something to navigate with less structure just because a medication is doing some of the work. If anything, it calls for more attention, more monitoring, and more intentional support around the child’s whole nutritional picture during a stage of life where their body is still very much under construction. Approaching it this way gives your child the best chance of benefiting from treatment while still growing and developing exactly the way they’re supposed to.